We also developed a novel macrophage membrane coated and PLGA-Dil based nanoplatform encapsulating FB23-2, an FTO inhibitor that suppresses diabetes associated endothelial phenotypes, thus providing a promising nanotherapeutic approach for DR. This evidence concerns the gene FTO and diabetes mellitus.